Sponsored by UCB Pharma Medical Affairs
AS/Spondyloarthritis
![](https://pbs.twimg.com/profile_images/1702756729/image_normal.jpg)
2 weeks 4 days ago
EFFECTIVENESS & COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPA (TeleSpA-STUDY): PRAGMATIC MULTICENTRE RVT cost effective but no one will ever be examined again especially for pathology outside joints! @rheumnow #EULAR2024
![](https://pbs.twimg.com/profile_images/1702756729/image_normal.jpg)
2 weeks 4 days ago
beautiful work Univ of Qld - rat SpA model bacterial dna into entheses blocked by 23i not 17i @RheumNow #EULAR2024 https://t.co/X9hzkA56d0
![](https://pbs.twimg.com/media/GQBh2sNWsAA96JE.jpg)
Extra-musculoskeletal manifestations (EMMs) occur in patients with spondyloarthritis.The prevalence of EMMs such as uveitis, psoriasis and inflammatory bowel disease are 26%, 9% and 7% respectively…
![](https://pbs.twimg.com/profile_images/1215290012490702848/mq73skc3_normal.jpg)
2 weeks 5 days ago
Long term safety of bimekizumab (BKZ) in ankylosing spondylitis (BE AGILE) study (n 296) shows sustained ASAS40 efficacy @wk 48 (52%) & wk256 (50%). Low AE for candidiasis (2.6%), SIE (1.4%), IBD (0.8/100PY), Uveitis (0.7/100PY) Abst# POS0215 #EULAR2024 https://t.co/9PWey3itu9
![](https://pbs.twimg.com/media/GP-rlpBXAAA0jhK.png)
![](https://pbs.twimg.com/profile_images/1007774150000332801/SjLeJk3G_normal.jpg)
2 weeks 5 days ago
#Editors Picks @eular_org @ARD_BMJ @ACR_Journals
Can #rheumatologists effectively #dx of #ankylosing #spondylitis?
đź‘Ť
552 pts - 1/3 axSpA w high certainty
Certainty of #dx changed over time
2 features
#sacroileitis
good #nSAID response
#EULAR2024 @RheumNow https://t.co/NN3GZTmgn9
![](https://pbs.twimg.com/media/GP83b9OXcAAxlF1.jpg)
![](https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg)
2 weeks 5 days ago
10 baseline predictors for achieving treatment response to Secukinumab in the EuroSpA study. Having non-radiographic disease was a negative predictor of obtaining LDA at 6 months and remaining on treatment at 12 months in European axSpA patients initiating secukinumab.… https://t.co/HrRnoDzSPP https://t.co/Gp1KZmPych
![](https://pbs.twimg.com/media/GP8aAz2XoAA0rZB.jpg)
![](https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg)
2 weeks 6 days ago
Extra musculoskeletal manifestations (EMMs) in spondyloarthritis #EULAR2024 OP0085 @RheumNow https://t.co/yRxPmMYLxn
![](https://pbs.twimg.com/media/GP4nvoXW4AEyCpV.jpg)
![](https://pbs.twimg.com/profile_images/926606033270665216/Z42VohYE_normal.jpg)
2 weeks 6 days ago
Increase in mSASSS over time was greater with increasing comorbidity burden. Increasing comorbidity burden is independently associated with greater radiographic progression #EULAR2024 OP0103 @RheumNow https://t.co/j7UblASUvC
![](https://pbs.twimg.com/media/GP4nJ3tXQAAm5wp.jpg)